DA5-CH

DA5-CH is a dual agonist of the glucagon-like peptide 1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, developed as a novel therapeutic candidate for neurodegenerative diseases, particularly Parkinson’s disease. Unlike many GLP-1 receptor agonists, DA5-CH is engineered to cross the blood-brain barrier at a higher rate, enabling direct central nervous system effects. In preclinical models of Parkinson’s disease, DA5-CH demonstrated superior efficacy compared to semaglutide and other GLP-1 analogs by reducing neuroinflammation (lowering IL-1β and TNF-α), protecting dopaminergic neurons in the substantia nigra, increasing tyrosine hydroxylase expression (enhancing dopamine synthesis), reducing α-synuclein aggregation, and improving insulin sensitivity in brain tissue. These properties suggest that DA5-CH may offer significant benefits for treating neurodegenerative disorders characterized by dopamine depletion and inflammation[1][2][3][4][5].